Keyword: Advanced Accelerator Applications
Novartis’ new Galaxies of Hope app was highlighted by Apple's App Store, helping to spur downloads of the game for the neuroendocrine tumor community.
Just months after picking up Advanced Accelerator Applications, Novartis is getting a quick boost with the U.S. approval for Lutathera.
Novartis' $3.9B deal for Advanced Accelerator Applications comes with a blockbuster-to-be, Lutathera, that could follow in Sandostatin's footsteps.
Despite megamerger deal speculation, Novartis has been pledging bolt-on deals, and the latest buzz says it has a $2.6 billion target in its sights.